PEA for IBS: the rare gut supplement with real trials, and the fine print.

Most supplements sold for IBS have nothing behind them. This one has actual randomised trials. That is the start of the question, not the end of it.

Most of the supplements marketed for irritable bowel syndrome have almost nothing behind them: a mechanism that sounds plausible, a headline, and no trial in actual patients. Palmitoylethanolamide, mercifully shortened to PEA, is one of the few exceptions. It has been through randomised, placebo-controlled trials in people with IBS. That alone puts it ahead of most of the shelf. It also does not settle the matter, and the gap between has trials and works is worth walking through, because it is exactly the distinction the label will not make for you.

PEA is a fatty molecule your own body makes, on demand, as a kind of internal dimmer switch for inflammation and pain. It works close to the same signalling system the body's own cannabis-like compounds use, and one of its main jobs is to calm mast cells, the immune cells that release histamine and other irritants when they are triggered. That connects to IBS directly. A good proportion of people with the condition have a gut lining that is quietly, chronically immune-activated, with more of those mast cells sitting close to the nerves that carry pain. A compound that settles mast cells is, on paper, a sensible thing to aim at that problem.

The evidence comes from two randomised trials, and it matters that both tested PEA combined with a second compound called polydatin, not PEA on its own. In the first, 54 adults with IBS took the combination or a placebo for twelve weeks; the treatment markedly reduced abdominal pain compared with placebo, although the mast-cell count it was supposed to bring down did not change (Cremon 2017). In the second, 70 children and teenagers with IBS took it or a placebo for twelve weeks, and significantly more of the treated group reached remission, with the clearest benefit in the diarrhoea-predominant type and a real drop in pain (Di Nardo 2024). Neither trial recorded safety problems.

So far, so encouraging. Then comes the fine print.

They are small trials. Fifty-four adults and seventy children is enough to be interesting and not enough to be sure, and effects in trials this size have a habit of shrinking as the studies get bigger. They tested a combination, so the evidence is for PEA-plus-polydatin together; the PEA-only capsules often on sale are a different product. And the work clusters around the same Italian research group, with the same lead author on both trials. That is no criticism of the science, but independent teams reproducing a finding in other countries is what turns promising into established, and that step has not really happened yet.

There is the question of what improved, too. The thing that moved was pain, which is fair enough, because pain is the symptom most people would hand back first. But IBS is also bowel habit, bloating, and urgency, and the mechanism PEA was meant to work through, calming those mast cells, did not clearly show up in the adult trial even as the pain got better. A recent review that gathered up the mast-cell-calming treatments tried in IBS, PEA and polydatin among them, called the overall evidence limited and most of the individual trials at some risk of bias, and asked for higher-quality studies before anyone draws firm conclusions (Coppens 2024).

This is why, in our own database, PEA sits at Grade B rather than higher or lower. It has real human trials, a mechanism that makes sense, a clean safety record so far, and a genuine effect on the symptom that matters most, which together are more than almost anything else marketed for IBS can claim. It is also small, combination-based, pain-focused, and not yet independently confirmed, which is why it is not Grade A. Grade B is the honest home for promising, and not proven.

If you want to give it a try, the useful version of the advice is specific. It is the PEA-plus-polydatin combination the trials tested, at the dose they used, aimed at pain rather than at fixing the whole syndrome, and worth judging for yourself over a few weeks rather than assuming. It has been clean on safety, which makes a fair trial reasonable. It is not a certainty, and any product that tells you it is has stopped describing the evidence and started selling you something.

Has some real evidence is an unglamorous place to stand, halfway between the hype that promises everything and the shrug that offers nothing. For a supplement and IBS, it is also, refreshingly, an honest one.